Citations 1
553 DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial
Uronis, Hope E. , Sirard, Cynthia A. , Kagey, Michael H. , Baum, Jason , Kim, In-Ho , Oh, Do‐Youn , Sym, Sun Jin , Tejani, Mohamedtaki Abdulaziz, Klempner, Samuel J. , Ajani, Jaffer A. , Chao, Joseph , Zhang, Lilin , Shim, Byoung Yong , Sonbol, Mohamad Bassam , Wainberg, Zev A. , Mahalingam, Devalingam , Lee, Keun‐Wook
Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A578-A578
